Showing 5141-5150 of 5644 results for "".
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants
- Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US IDE Trial for iStent infinitehttps://modernod.com/news/glaukos-achieves-pipeline-milestone-with-completion-of-patient-enrollment-in-us-ide-trial-for-istent-infinite/2476990/Glaukos announced the completion of patient enrollment in its FDA Investigational Device Exemption (IDE) trial for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is designed for use in a standalone procedure to reduce elevated IOP in refractory glaucoma patients. I
- Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/Aerpio Pharmaceuticals announced interim results from its phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG). The phase 1b study is an ongoing randomized, double-masked study designed to assess
- Alcon Celebrates World Sight Day, Strengthens Commitment to Enhancing Global Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-strengthens-commitment-to-enhancing-global-access-to-eye-care/2476983/Thousands of Alcon associates worldwide are participating in activities to support the advancement of eye health in honor of World Sight Day. To celebrate the occasion, the company announced a theme for the upcoming year, “Alcon: The Official Sponsor of 20/20,” which is designed to highlight its
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Mynosys Secures $25 Million Investment; Names Rob Thornhill as CEOhttps://modernod.com/news/mynosys-secures-25-million-investment-names-rob-thornhill-as-ceo/2476976/Mynosys Cellular Devices, manufacturer of the Zepto cataract surgery device, announced it finalized a $25 million financing round, led by Decheng Capital, and named veteran ophthalmology industry executive Rob Thornhill as Chief Executive Officer. This financing provides capital to fuel U.
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstenthttps://modernod.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/Ivantis announced that it has completed enrollment in its SPECTRUM, which the company calls the largest single-device registry in ophthalmology. SPECTRUM is a patient registry for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate
- Ocutrx Unveils ORLenz for Surgery Visualization Technology in ARWear Headsethttps://modernod.com/news/ocutrx-unveils-orlenz-for-surgery-visualization-technology-in-arwear-headset/2476972/Ocutrx Vision Technologies is revealing a next-generation AR headset technology for surgery visualization called the ORLenz. A prototype of this technology is being formally introduced at the American Academy of Ophthalmology 2019 Conference in San Francisco. The ORLenz is a second medical device